

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]


Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	General
Servier Laboratories (vorasidenib)	 All Wales Therapeutics and Toxicology Centre
 Patient/carer groups Astro Brain Tumour Fund Beacon Black Health Agency for Equality Brain and Spine Foundation Brain Tumour Charity Brain Tumour Research Brainstrust British Brain Tumour Association Cancer 52 Cancer Black Care Cancer Equality Childhood Cancer Patients Alliance Children with Cancer Headcase Cancer Trust Independent Cancer Patients Voice 	 Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 International Brain Tumour Alliance Macmillan Cancer Support Maggie's Centres Marie Curie Neurological Alliance Solving Kids Cancer South Asian Health Foundation Specialised Healthcare Alliance Teenage Cancer Trust Tenovus Cancer Care The Brain Charity Young Lives vs Cancer Healthcare professional groups	 Comparator companies None Relevant research groups Andrew McCartney Trust Fund for Brain Tumour Research Brain Tumour Research Cochrane Childhood Cancer Group Genomics England Institute of Cancer Research Institute of Neurology, UCL MRC Clinical Trials Unit National Institute for Health Research
 Association of British Neurologists Association of Cancer Physicians 	Oracle Cancer TrustTessa Jowell Brain Cancer Mission

Final stakeholder list for the evaluation of vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407] Issue date: November 2024



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Association of Surgeons of Great Britain and Ireland British Association of Head and Neck Oncologists British Association of Surgical Oncology British Geriatrics Society British Institute of Radiology British Neuro-Oncology Society British Oncology Pharmacy Association British Psychosocial Oncology Society British Skull Base Society Cancer Research UK Children's Cancer & Leukaemia Group National Neuroscience Advisory Group Neonatal and Paediatric Pharmacists Group Royal College of Anaesthetists Royal College of General Practitioners Royal College of Paediatrics and Child Health Royal College of Pathologists Royal College of Pathologists Royal College of Pathologists Royal College of Surgeons Royal College of Surgeons Royal College of Surgeons Royal College of Radiologists Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers Society of British Neurological Surgeons UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care Health Technology Wales (HTW) NHS England 	Associated Public Health groups Public Health Wales UK Health Security Agency



NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.